Palvella to Unveil Phase 3 and Phase 2 Data for QTORIN™ Rapamycin at ISSVA Congress
Event summary
- Palvella Therapeutics will present Phase 3 SELVA and Phase 2 TOIVA study results for QTORIN™ rapamycin at ISSVA World Congress 2026 on May 20.
- James Treat, MD, from Children’s Hospital of Philadelphia, will deliver the late-breaking abstract presentation.
- QTORIN™ rapamycin is being developed for microcystic lymphatic malformations and cutaneous venous malformations.
The big picture
Palvella’s presentation at ISSVA comes as the biopharmaceutical sector intensifies focus on rare disease treatments, particularly those targeting vascular anomalies. The company is positioning itself as a leader in this niche, leveraging its QTORIN™ platform to address unmet medical needs. Success here could validate Palvella’s pipeline strategy and attract further investment.
What we're watching
- Regulatory Pathway
- Whether the Phase 3 SELVA data will support a Breakthrough Therapy Designation for QTORIN™ rapamycin.
- Clinical Validation
- The pace at which Palvella can translate positive Phase 2 TOIVA results into further clinical development.
- Market Positioning
- How Palvella differentiates QTORIN™ rapamycin in the competitive landscape of rare disease therapies.
Related topics